Clinical Spectrum and Outcome of Pediatric Drug Induced Liver Injury
Limited literature is available in pediatric population regarding drug-induced liver injury (DILI) making it a diagnostic challenge. This study was thus planned to determine the clinical spectrum and the outcome of DILI in children. All patients with DILI under 18 y of age were retrospectively reviewed and details regarding clinical presentation, Roussel Uclaf Causality Assessment Method (RUCAM) scale, drugs implicated, biochemical abnormalities and outcome were noted. DILI constituted 3.7% of all children with liver disease. Cases were divided into the hepatocellular (18, 50%), cholestatic (10, 27.8%), and mixed pattern (8, 22.2%). Complementary and alternative medicines (CAM) and antitubercular (ATT) drugs accounted for three-fourth cases of total DILI (39% and 33% cases respectively). Overall, 4 (11%) patients died and 5 (14%) patients progressed to chronic DILI. Presence of ascites, non-hepatocellular injury pattern and high serum total IgG levels were significantly associated with unfavourable outcome (death or chronicity).
KeywordsPediatric drug induced liver injury Roussel Uclaf Causality Assessment Method (RUCAM) scale Complementary and alternative medicines
AK, VS, SKV and NM: Conceptualisation and design of study, acquisition, analysis and review of data, preparation of first draft; RK, SA and DR: Conceptualisation and design of study, critical review, statistical guidance, revision and approval of the final version. SA will act as guarantor for the paper.
Compliance with Ethical Standards
Conflict of Interest
Source of Funding
- 3.Molleston JP, Fontana RJ, Lopez MJ, Kleiner DE, Gu J, Chalasani N; Drug-Induced Liver Injury Network. Characteristics of drug induced liver injury in children: interim results from the DILIN prospective study. J Pediatr Gastroenterol Nutr. 2011;53:182–9.Google Scholar
- 6.García-Cortés M, Stephens C, Lucena MI, Fernández-Castañer A, Andrade RJ; Spanish Group for the Study of Drug-Induced Liver Disease (Grupo de Estudio para las Hepatopatías Asociadas a Medicamentos GEHAM). Causality assessment methods in drug induced liver injury: strengths and weaknesses. J Hepatol. 2011;55:683–91.Google Scholar
- 7.Squires RH Jr, Shneider BL, Bucuvalas J, et al. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr. 2006;148:652–8.Google Scholar
- 8.Sarin SK, Kedarisetty CK, Abbas Z, et al; APASL ACLF Working Party. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the liver (APASL) 2014. Hepatol Int. 2014;8:453–71.Google Scholar
- 9.Chalasani NP, Hayashi PH, Bonkovsky HL, et al; Practice Parameters Committee of the American College of Gastroenterology. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109:950–66.Google Scholar